



## 4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

August 12, 2024

EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 4<sup>th</sup> Annual Ophthalmology Virtual Conference. Members of the management team will also be available for one-on-one meetings.

### H.C. Wainwright 4<sup>th</sup> Annual Ophthalmology Virtual Conference

Presentation Date: Thursday, August 15, 2024  
Presentation Time: 12:00 p.m. ET  
Webcast Link: [Webcast](#)

An archived copy of the webcast will be available for up to one year by visiting the "Investors" section of the 4DMT website at <https://ir.4dmolecularterapeutics.com/events>.

### About 4DMT

4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT's proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at [www.4DMT.com](http://www.4DMT.com) and follow us on [LinkedIn](#).

### Contacts:

#### Media:

Katherine Smith  
Inizio Evoke Comms  
[Katherine.Smith@inizioevoke.com](mailto:Katherine.Smith@inizioevoke.com)

#### Investors:

Julian Pei  
Head of Investor Relations and Corporate Finance  
[Investor.Relations@4DMT.com](mailto:Investor.Relations@4DMT.com)